Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

KAPA

Kairos Pharma Ltd

Nov 14 • 04:00PM ET

0.8294

+0.0384 4.85 %

Healthcare • Biotechnology • USA • AMEX

Index	-	P/E	-	EPS (ttm)	-0.30	Insider Own	38.38%	Shs Outstand	20.82M	Perf Week	-2.72%
Market Cap	17.20M	Forward P/E	-	EPS next Y	-0.37	Insider Trans	0.00%	Shs Float	12.78M	Perf Month	-29.11%
Enterprise Value	11.62M	PEG	-	EPS next Q	-0.07	Inst Own	2.03%	Short Float	1.87%	Perf Quarter	-29.11%
Income	-5.06M	P/S	-	EPS this Y	0.00%	Inst Trans	-15.62%	Short Ratio	0.26	Perf Half Y	33.56%
Sales	0.00M	P/B	2.25	EPS next Y	-60.87%	ROA	-77.46%	Short Interest	0.24M	Perf YTD	-45.43%
Book/sh	0.37	P/C	3.08	EPS next 5Y	-29.25%	ROE	-92.07%	52W High	3.25 -74.48%	Perf Year	-59.63%
Cash/sh	0.27	P/FCF	-	EPS past 3/5Y	-4.30% -23.37%	ROIC	-66.05%	52W Low	0.40 107.35%	Perf 3Y	-
Dividend Est.	-	EV/EBITDA	-	Sales past 3/5Y	- -	Gross Margin	-	Volatility	9.76% 8.12%	Perf 5Y	-
Dividend TTM	-	EV/Sales	-	EPS Y/Y TTM	-101.60%	Oper. Margin	-	ATR (14)	0.09	Perf 10Y	-
Dividend Ex-Date	-	Quick Ratio	16.56	Sales Y/Y TTM	-	Profit Margin	-	RSI (14)	36.45	Recom	1.00
Dividend Gr. 3/5Y	- -	Current Ratio	16.56	EPS Q/Q	15.09%	SMA20	-17.16%	Beta	2.38	Target Price	8.33
Payout	-	Debt/Eq	0.00	Sales Q/Q	-	SMA50	-31.54%	Rel Volume	0.45	Prev Close	0.79
Employees	4	LT Debt/Eq	0.00	Earnings	Sep 03	SMA200	-17.93%	Avg Volume	933.10K	Price	0.83
IPO	Sep 16, 2024	Option/Short	No / Yes	EPS/Sales Surpr.	7.14% -	Trades		Volume	428,082	Change	4.85%

Sep-19-25 07:25AM	Kairos Pharma reports positive data from Phase II prostate cancer treatment trial (Clinical Trials Arena) -8.96%
Jul-28-25 12:28PM	CEO.CA's Inside the Boardroom: Kairos Pharma CEO on Phase 2 Safety Data, 165% Stock Move & September Efficacy Timeline (Newsfile) -6.09%
Jul-16-25 08:30AM	Kairos Pharma Announces Participation and Presentation in the H.C. Wainwright 27th Annual Global Investment Conference September 8-10, 2025 (Business Wire) -6.84%
Jul-15-25 08:00AM	Kairos Pharma Announces Positive Safety Results from Phase 2 Trial of ENV-105 in Advanced Prostate Cancer (Business Wire) +70.78%
Jun-03-25 08:15AM	Kairos Pharma Ltd. Announces New Data on Small Molecule GITR Ligand Agonist KROS 101 as Promising Cancer Immunotherapy at the American Society of Clinical Oncology (ASCO) 2025 Annual Meeting (Business Wire) -23.51%
08:00AM	Loading…
May-06-25 08:00AM	Kairos Pharma, Ltd. Announces Participation in the D. Boral Capital Inaugural Global Conference (Newsfile)
Apr-28-25 08:00AM	Kairos Pharma, Ltd. Announces Data to be Presented at the American Society of Clinical Oncology (ASCO) 2025 Annual Meeting (Business Wire)
Apr-24-25 08:00AM	Kairos Pharma Ltd. Provides Letter to Stockholders (Business Wire)
Apr-17-25 08:00AM	Kairos Pharma Ltd. Announces Department of Defense Grant to Support Its Study of Lead Compound ENV105 to Prevent Drug Resistance in Lung Cancer (Business Wire) +5.80%
Apr-04-25 09:40AM	Block upgraded, Nvidia downgraded: Wall Streets top analyst calls (TipRanks) +12.77%
Mar-31-25 07:00AM	Kairos Pharma Ltd. Announces Completed Enrollment of the Safety Arm of Its Phase 2 Clinical Trial of ENV105 in Metastatic, Castration-Resistant Prostate Cancer (Business Wire)
Mar-28-25 09:03AM	CEO.CA's Inside the Boardroom: Kairos Pharma's Breakthrough Cancer Treatment & What's Next for ENV105 (Newsfile) -5.01%
Mar-27-25 04:05PM	Kairos Pharma Ltd. Highlights Participation in Recent and Upcoming Scientific and Industry Events (Business Wire)
Mar-20-25 07:30AM	Kairos Pharma Ltd. Announces Peer Reviewed Publication Highlighting Potentially Groundbreaking Discovery in Overcoming Drug Resistance in Non-Small Cell Lung Cancer (Business Wire)
Feb-26-25 07:00AM	Kairos Pharma Presents Preclinical Data on its Investigational Compounds KROS 101 and KROS 401 Further Supporting Both Compounds Potential as Therapeutics for Melanoma and Glioblastoma (Business Wire) +8.77%
08:30AM	Loading…
Feb-18-25 08:30AM	Kairos Pharma Announces New Department of Defense Funding for Research of ENV205 (Business Wire)
Feb-11-25 08:30AM	Kairos Pharma Adds Huntsman Cancer Institute for Phase 2 ENV105 Clinical Trial (Business Wire)
Feb-06-25 08:30AM	Kairos Pharma Oral Presentation on Its Investigational Compound KROS 101 at the 13th AACR-JCA Joint Conference Supports the Compounds Potential as a Therapeutic for Melanoma and Glioblastoma (Business Wire) -8.86%
Jan-28-25 08:15AM	Kairos Pharma to Present Short Talk on Its Investigational Compound KROS 101 at the 13th AACR-JCA Joint Conference February 5, 2024 (Business Wire)
Jan-21-25 08:30AM	Kairos Pharma Provides Business Update and Outlook into 2025 (Business Wire) -8.09%
Jan-07-25 08:15AM	Kairos Pharma to Present at the Lytham Partners Investor Healthcare Summit (Business Wire)
Dec-16-24 12:15PM	Kairos Pharma to Participate in The Microcap Conference in January 2025 (ACCESSWIRE)
Dec-03-24 08:30AM	Kairos Pharma Adds City of Hope Cancer Center for Phase 2 ENV105 Clinical Trial (Business Wire)
Nov-19-24 08:30AM	Kairos Pharma Approved to Dual List on Upstream (GlobeNewswire) -14.04%
Oct-22-24 09:00AM	Kairos Pharma to Present at the LD Micro Main Event XVII (GlobeNewswire)
Oct-14-24 06:00AM	Kairos Pharma (NYSEAmerican: KAPA): Advancing New Strategies to Overcome Cancer Treatment Challenges (News Direct) +7.80%
Oct-09-24 04:30PM	Kairos Pharma to Participate in a Fireside Chat at the 2024 Maxim Healthcare Virtual Summit (GlobeNewswire)
Sep-24-24 04:20PM	Kairos Pharma Enters Agreement with PreCheck Health Services to Develop Biomarkers to Identify Patients Responsive to ENV105 to Target Cancer Drug Resistance in Prostate and Lung Cancer Patients (GlobeNewswire) -7.46%
Sep-17-24 04:29PM	Kairos Pharma Closing of $6.2 Million Initial Public Offering (GlobeNewswire) -5.38% -6.50%
Sep-16-24 10:49AM	Kairos Pharma Prices $6.2 Million Initial Public Offering (GlobeNewswire)

Kairos Pharma Ltd. is a clinical-stage biopharmaceutical company, which engages in the development of novel and transformative drug therapies to treat cancer. It focuses on the research and development of immunotherapies for oncology. The company was founded by John S. Yu on June 17, 2013 and is headquartered in Los Angeles, CA.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Murali Ramachandran	VP of Research and Development	Nov 25 '24	Buy	1.59	200	318	133,057	Nov 25 08:30 PM
Samuelson Doug	Chief Financial Officer	Nov 22 '24	Buy	1.50	2,500	3,750	60,796	Nov 25 06:03 AM
Yu John S	CEO and Chairman	Nov 20 '24	Buy	1.44	4,000	5,760	5,341,837	Nov 21 09:53 PM

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

KAPA

Kairos Pharma Ltd

Upgrade your FINVIZ experience